Project Grant R15HL184202
Award Date 9/1/26
Completion Date 5/31/29
Dollars Obligated $461K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Bellingham, WA 98225, USA
Similar Awards
- The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Washington $2,647,494 on May 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop computational and experimental models of myosin variants that determine how single amino acid variants affect myosin structure and function across multiple scales. The project integrates molecular and Brownian dynamics simulations of the chemo-mechanical cycle of β-myosin, generated from human crystal and...
- The National Heart, Lung, and Blood Institute awarded Seattle Children's Hospital, doing business as Seattle Children's Research Institute, $1,839,440 on August 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate how heavy chain hyaluronan and TSG-6 modulate lung inflammation during respiratory syncytial virus (RSV) infection. The research examines the extracellular matrix's role in RSV pathogenesis, focusing on age-dependent inflammation in young children....
- The National Heart, Lung, and Blood Institute, under the Department of Health and Human Services National Institutes of Health, awarded The Washington University $768,128 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to mechanistically evaluate the role of oscillatory shear stress in deep vein thrombosis prevention. The recipient will conduct in vitro, in vivo, and human model studies to determine whether restoration of oscillatory shear stress in veins...
- The National Heart, Lung, and Blood Institute awarded New York University $836,736 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate endothelial mechanosensing of circulatory flow in health and disease. The project will examine how endothelial cells lining blood and lymphatic vessels respond to fluid flow forces, with focus on the roles of PLXND1 (a transmembrane semaphorin receptor) and KLF2 (a transcription factor) in endothelial responses to...
- The National Heart, Lung, and Blood Institute awarded the University of Pittsburgh $248,967 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support research dissecting vascular reperfusion and remodeling after injury in zebrafish models. The award funds investigation into how delayed vascular reperfusion contributes to chronic, non-healing wounds affecting approximately two percent of the U.S. population. The research examines molecular mechanisms...
- The National Heart, Lung, and Blood Institute awarded Yale University $1.68 million under the Cardiovascular Diseases Research program (CFDA 93.837) on July 1, 2026, to investigate developmental mechanisms driving vascular resiliency in the brain's Circle of Willis. The funded research uses zebrafish and human induced pluripotent stem cell vascular organoids to uncover how loss of the microRNA mir-125a impairs embryonic brain angiogenesis and leads to incomplete Circle of Willis formation with...
- The National Heart, Lung, and Blood Institute awarded The Washington University $803,772 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of the mitochondrial calcium uniporter in platelet function and thrombosis. The research addresses ischemic stroke prevention through basic and translational science. Approximately 700,000 people in the United States experience ischemic stroke annually, and current acute treatments restrict...
- The National Heart, Lung, and Blood Institute, part of the Department of Health and Human Services National Institutes of Health, awarded $539,066 to Massachusetts General Hospital (The General Hospital Corporation, Research Management Division) on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research investigating the role of microglial extracellular vesicles in the progression of atherosclerosis following traumatic brain injury. The...
- The National Heart, Lung, and Blood Institute awarded the University of Washington $777,814 on August 15, 2026, to develop computational methods for enhanced clinical use of single-cell data under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds development of novel analytical frameworks to extract clinically actionable biomarkers from single-cell data generated by flow cytometry and other clinical technologies. The project addresses three gaps in current...
- The National Heart, Lung, and Blood Institute awarded University of Massachusetts Medical School $103,686 on December 12, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to support basic research into translation control mechanisms in heart and lung disease. The funded research investigates how the RNase A family nuclease angiogenin stimulates blood vessel formation and why angiogenin dysfunction associates with heart failure, and separately examines how the bacterial...